CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 91 enrolled
Drug / intervention
hypofractionationradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00809991
NCT00809991Phase 2Completed
CompareCT.gov

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Dec 17, 2008·Updated Feb 18, 2026

In Brief

A Phase 2 clinical trial evaluating hypofractionation for Prostate Cancer. Completed, enrolled 91 participants across 1 site.

Detailed Summary

This will be a Phase II study evaluating the effectiveness and toxicity of a specific radiation therapy regimen. This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens. The total dose is calculated to be effective for late effects which has been shown to be effective and safe in a large prospective Phase II study. If the hypothesis for the prostate is is true, then this regimen should be at least as effective or more effective for tumor control than the current conventional therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2008
Enrollment StartDec 22, 2008
Primary CompletionJul 24, 2024
Study CompletionSep 1, 2025
TodayJul 2, 2026
Enrollment to primary: 15.6 yearsPosted 17.5 years ago

Interventions

hypofractionationradiation

3.6 Gy per day to a total dose of 57.6 Gy (16 fractions).